FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108784809> ?p ?o ?g. }

• W3108784809 abstract "Summary Neuroblastoma is a pediatric tumor originating from the sympathetic nervous system responsible for 10-15 percent of all childhood cancer deaths. Half of all neuroblastoma patients present with high-risk disease at diagnosis. Despite intensive multi-modal therapies nearly 50 percent of high-risk cases relapse and die of their disease. In contrast to the overall paucity of mutations, high-risk neuroblastoma nearly invariably present with recurrent somatic segmental chromosome copy number variants. For several focal aberrations ( e.g. MYCN and LIN28B amplification), the direct role in tumor formation has been established. However, for recurrent aberrations, such as chromosome 2p and 17q gains, the identification of genes contributing to tumor initiation or progression has been challenging due to the scarcity of small segmental gains or amplifications. In this study, we identified and functionally evaluated the ribonucleotide reductase regulatory subunit 2 (RRM2) as a top-ranked 2p putative co-driver and therapeutic target in high-risk neuroblastoma enforcing replicative stress resistance. In vitro knock down and pharmacological RRM2 inhibition highlight RRM2 dependency in neuroblastoma cells, further supported by the finding that co-overexpression of RRM2 in a dβh-MYCN transgenic zebrafish line increased tumor penetrance with 80% and accelerated tumor formation. Given the critical role of RRM2 in replication fork progression and regulation of RRM2 through ATR/CHK1 signaling, we tested combined RRM2 and ATR/CHK1 small molecule inhibition with triapine and BAY1895344/prexasertib respectively, and observed strong synergism, in particular for combined RRM2 and CHK1 inhibition. Transcriptome analysis following combinatorial drugging revealed HEXIM1 as one of the strongest upregulated genes. Using programmable DNA binding of dCas9 with a promiscuous biotin ligase, RRM2 promotor bound proteins were identified including HEXIM1 and NurRD complex members, supporting a cooperative role for HEXIM1 upregulation together with CHK1 inhibition in further attenuating RRM2 expression levels. We evaluated the impact of combined RRM2/CHK1 inhibition in vivo , with treatment of a murine xenograft model showing rapid and complete tumor regression, without tumor regrowth upon treatment arrest. In conclusion, we identified RRM2 as a novel dependency gene in neuroblastoma and promising target for synergistic drug combinations with small compounds targeting DNA checkpoint regulators." @default.
• W3108784809 created "2020-12-07" @default.
• W3108784809 creator A5006777171 @default.
• W3108784809 creator A5010644426 @default.
• W3108784809 creator A5012655376 @default.
• W3108784809 creator A5017179085 @default.
• W3108784809 creator A5018610456 @default.
• W3108784809 creator A5021582671 @default.
• W3108784809 creator A5023357394 @default.
• W3108784809 creator A5026950879 @default.
• W3108784809 creator A5027345995 @default.
• W3108784809 creator A5029457295 @default.
• W3108784809 creator A5031701521 @default.
• W3108784809 creator A5032769404 @default.
• W3108784809 creator A5035169105 @default.
• W3108784809 creator A5047878026 @default.
• W3108784809 creator A5049167671 @default.
• W3108784809 creator A5050006580 @default.
• W3108784809 creator A5050883617 @default.
• W3108784809 creator A5051116129 @default.
• W3108784809 creator A5054092663 @default.
• W3108784809 creator A5055956862 @default.
• W3108784809 creator A5060237299 @default.
• W3108784809 creator A5060684280 @default.
• W3108784809 creator A5061831442 @default.
• W3108784809 creator A5062364819 @default.
• W3108784809 creator A5068075623 @default.
• W3108784809 creator A5071314432 @default.
• W3108784809 creator A5071576476 @default.
• W3108784809 creator A5073525735 @default.
• W3108784809 creator A5073903716 @default.
• W3108784809 creator A5078982772 @default.
• W3108784809 creator A5079095237 @default.
• W3108784809 creator A5082756197 @default.
• W3108784809 creator A5086163487 @default.
• W3108784809 creator A5087988858 @default.
• W3108784809 date "2020-11-26" @default.
• W3108784809 modified "2023-10-11" @default.
• W3108784809 title "RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma" @default.
• W3108784809 cites W1855851918 @default.
• W3108784809 cites W1980181290 @default.
• W3108784809 cites W1984373702 @default.
• W3108784809 cites W1985387098 @default.
• W3108784809 cites W2032767287 @default.
• W3108784809 cites W2044033792 @default.
• W3108784809 cites W2044334920 @default.
• W3108784809 cites W2050293032 @default.
• W3108784809 cites W2054013802 @default.
• W3108784809 cites W2085246002 @default.
• W3108784809 cites W2107632586 @default.
• W3108784809 cites W2110735746 @default.
• W3108784809 cites W2112582433 @default.
• W3108784809 cites W2118023637 @default.
• W3108784809 cites W2161954865 @default.
• W3108784809 cites W2181205541 @default.
• W3108784809 cites W2209936495 @default.
• W3108784809 cites W2330148258 @default.
• W3108784809 cites W2415880685 @default.
• W3108784809 cites W2425235023 @default.
• W3108784809 cites W2540036007 @default.
• W3108784809 cites W2546675038 @default.
• W3108784809 cites W2551596349 @default.
• W3108784809 cites W2741613334 @default.
• W3108784809 cites W2788084906 @default.
• W3108784809 cites W2788562722 @default.
• W3108784809 cites W2797725119 @default.
• W3108784809 cites W2799540870 @default.
• W3108784809 cites W2801382830 @default.
• W3108784809 cites W2889212290 @default.
• W3108784809 cites W2898434771 @default.
• W3108784809 cites W2915645504 @default.
• W3108784809 cites W2923898584 @default.
• W3108784809 cites W2937151884 @default.
• W3108784809 cites W2981993825 @default.
• W3108784809 cites W2985349530 @default.
• W3108784809 cites W4248412843 @default.
• W3108784809 cites W4256321774 @default.
• W3108784809 doi "https://doi.org/10.1101/2020.11.25.397323" @default.
• W3108784809 hasPublicationYear "2020" @default.
• W3108784809 type Work @default.
• W3108784809 sameAs 3108784809 @default.
• W3108784809 citedByCount "3" @default.
• W3108784809 countsByYear W31087848092021 @default.
• W3108784809 countsByYear W31087848092022 @default.
• W3108784809 crossrefType "posted-content" @default.
• W3108784809 hasAuthorship W3108784809A5006777171 @default.
• W3108784809 hasAuthorship W3108784809A5010644426 @default.
• W3108784809 hasAuthorship W3108784809A5012655376 @default.
• W3108784809 hasAuthorship W3108784809A5017179085 @default.
• W3108784809 hasAuthorship W3108784809A5018610456 @default.
• W3108784809 hasAuthorship W3108784809A5021582671 @default.
• W3108784809 hasAuthorship W3108784809A5023357394 @default.
• W3108784809 hasAuthorship W3108784809A5026950879 @default.
• W3108784809 hasAuthorship W3108784809A5027345995 @default.
• W3108784809 hasAuthorship W3108784809A5029457295 @default.
• W3108784809 hasAuthorship W3108784809A5031701521 @default.
• W3108784809 hasAuthorship W3108784809A5032769404 @default.
• W3108784809 hasAuthorship W3108784809A5035169105 @default.
• W3108784809 hasAuthorship W3108784809A5047878026 @default.
• W3108784809 hasAuthorship W3108784809A5049167671 @default.

• next